GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » 6-1 Month Momentum %

StageZero Life Sciences (TSX:SZLS) 6-1 Month Momentum % : N/A% (As of Apr. 30, 2024)


View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-30), StageZero Life Sciences's 6-1 Month Momentum % is N/A%.

The industry rank for StageZero Life Sciences's 6-1 Month Momentum % or its related term are showing as below:

TSX:SZLS's 6-1 Month Momentum % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: -2.85
* Ranked among companies with meaningful 6-1 Month Momentum % only.

Competitive Comparison of StageZero Life Sciences's 6-1 Month Momentum %

For the Diagnostics & Research subindustry, StageZero Life Sciences's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


StageZero Life Sciences's 6-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's 6-1 Month Momentum % falls into.



StageZero Life Sciences  (TSX:SZLS) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


StageZero Life Sciences  (TSX:SZLS) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


StageZero Life Sciences 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


StageZero Life Sciences (TSX:SZLS) Business Description

Traded in Other Exchanges
Address
70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2
StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines